EA201391097A1 - СОЕДИНЕНИЯ ДЛЯ СНИЖЕНИЯ ВЫРАБОТКИ β-АМИЛОИДА - Google Patents

СОЕДИНЕНИЯ ДЛЯ СНИЖЕНИЯ ВЫРАБОТКИ β-АМИЛОИДА

Info

Publication number
EA201391097A1
EA201391097A1 EA201391097A EA201391097A EA201391097A1 EA 201391097 A1 EA201391097 A1 EA 201391097A1 EA 201391097 A EA201391097 A EA 201391097A EA 201391097 A EA201391097 A EA 201391097A EA 201391097 A1 EA201391097 A1 EA 201391097A1
Authority
EA
Eurasian Patent Office
Prior art keywords
compounds
reduce
amyloid
development
production
Prior art date
Application number
EA201391097A
Other languages
English (en)
Inventor
Кеннет М. Бой
Джейсон М. Гернон
Джон Е. Макор
Ричард Е. Олсон
Цзяньлян Ши
Лорин А. Томпсон, III
Юн-Цзинь У
Ли СЮЙ
Юньхуй Чзан
Дмитрий С. Зуев
Original Assignee
Бристол-Маерс Сквибб Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Бристол-Маерс Сквибб Компани filed Critical Бристол-Маерс Сквибб Компани
Publication of EA201391097A1 publication Critical patent/EA201391097A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

Настоящее изобретение относится к сериям соединений формулы (I)которые снижают выработку β-амилоидного пептида (β-АР) и являются пригодными для лечения болезни Альцгеймера и других состояний, зависимых от выработки β-амилоидного пептида (β-АР).
EA201391097A 2011-01-28 2012-01-26 СОЕДИНЕНИЯ ДЛЯ СНИЖЕНИЯ ВЫРАБОТКИ β-АМИЛОИДА EA201391097A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161437279P 2011-01-28 2011-01-28
PCT/US2012/022665 WO2012103297A1 (en) 2011-01-28 2012-01-26 COMPOUNDS FOR THE REDUCTION OF β-AMYLOID PRODUCTION

Publications (1)

Publication Number Publication Date
EA201391097A1 true EA201391097A1 (ru) 2013-11-29

Family

ID=45688981

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201391097A EA201391097A1 (ru) 2011-01-28 2012-01-26 СОЕДИНЕНИЯ ДЛЯ СНИЖЕНИЯ ВЫРАБОТКИ β-АМИЛОИДА

Country Status (15)

Country Link
US (1) US8710061B2 (ru)
EP (1) EP2668168B1 (ru)
JP (1) JP5908499B2 (ru)
KR (1) KR20140014152A (ru)
CN (1) CN103328451B (ru)
AR (1) AR084944A1 (ru)
AU (1) AU2012211301B2 (ru)
BR (1) BR112013018298A2 (ru)
CA (1) CA2825906A1 (ru)
EA (1) EA201391097A1 (ru)
IL (1) IL226677A (ru)
MX (1) MX2013008699A (ru)
SG (1) SG191840A1 (ru)
TW (1) TW201309655A (ru)
WO (1) WO2012103297A1 (ru)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9730447B2 (en) 2013-04-15 2017-08-15 E I Du Pont De Nemours And Company Fungicidal amides
WO2016080516A1 (ja) * 2014-11-21 2016-05-26 味の素株式会社 Ｄｒｐ１重合阻害剤
CN107801397B (zh) * 2015-02-13 2021-07-30 达纳－法伯癌症研究所公司 Lrrk2抑制剂及其制备和使用方法
CN105017046A (zh) * 2015-07-15 2015-11-04 上海博康精细化工有限公司 一种4-环丙胺基丁酸乙酯的制备方法
EP3354653B1 (en) * 2015-07-21 2019-09-04 Guangzhou Maxinovel Pharmaceuticals Co. Ltd. Fused ring pyrimidine compound, intermediate, and preparation method, composition and use thereof
JP7335242B2 (ja) * 2017-11-27 2023-08-29 エフ． ホフマン－ラ ロシュ アーゲー ピリミジン誘導体
AU2020214064B2 (en) * 2019-01-29 2022-10-20 Shandong Xuanzhu Pharma Co., Ltd. Hexone glucokinase inhibitor and use thereof
CN112028839B (zh) * 2020-09-30 2022-04-12 中国海洋大学 一种医药中间体环烷烃并嘧啶二酮化合物的合成方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1318997T1 (sl) * 2000-09-15 2006-12-31 Vertex Pharma Pirazolne spojine, uporabne kot inhibitorji protein-kinaze
EP2226315A4 (en) * 2007-12-28 2012-01-25 Carna Biosciences Inc 2-AMINOQUINAZOLINE DERIVATIVE
TW201030002A (en) * 2009-01-16 2010-08-16 Bristol Myers Squibb Co Bicyclic compounds for the reduction of beta-amyloid production
TWI468402B (zh) * 2009-07-31 2015-01-11 必治妥美雅史谷比公司 降低β－類澱粉生成之化合物
US8637525B2 (en) * 2009-07-31 2014-01-28 Bristol-Myers Squibb Company Compounds for the reduction of beta-amyloid production

Also Published As

Publication number Publication date
EP2668168B1 (en) 2017-03-01
JP2014503590A (ja) 2014-02-13
AR084944A1 (es) 2013-07-10
AU2012211301A1 (en) 2013-09-19
BR112013018298A2 (pt) 2016-11-16
US20130030011A1 (en) 2013-01-31
MX2013008699A (es) 2013-08-21
SG191840A1 (en) 2013-08-30
AU2012211301B2 (en) 2016-02-25
CN103328451B (zh) 2015-06-10
CA2825906A1 (en) 2012-08-02
KR20140014152A (ko) 2014-02-05
EP2668168A1 (en) 2013-12-04
IL226677A (en) 2014-11-30
WO2012103297A1 (en) 2012-08-02
US8710061B2 (en) 2014-04-29
CN103328451A (zh) 2013-09-25
JP5908499B2 (ja) 2016-04-26
TW201309655A (zh) 2013-03-01

Similar Documents

Publication Publication Date Title
EA201270225A1 (ru) СОЕДИНЕНИЯ ДЛЯ УМЕНЬШЕНИЯ ПРОДУКЦИИ β-АМИЛОИДА
EA201270824A1 (ru) Соединения для уменьшения продукции бета-амилоида
EA201391097A1 (ru) СОЕДИНЕНИЯ ДЛЯ СНИЖЕНИЯ ВЫРАБОТКИ β-АМИЛОИДА
EA201891833A1 (ru) Комбинация для лечения амиотрофического бокового склероза или родственных болезней
EA201690153A1 (ru) Замещенные бензофуранильные и бензоксазолильные соединения и их применения
NZ712207A (en) Tetrahydropyrrolothiazine compounds
EA201201374A1 (ru) Лечение атаксии-телеангиэктазии
EA201490650A1 (ru) Фармацевтические композиции
EA201790764A1 (ru) Новые соединения карбоновых кислот, подходящие для ингибирования микросомальной простагландин-e2-синтазы 1
EA201490747A1 (ru) 1-арилкарбонил-4-оксипиперидиновые соединения, полезные для лечения нейродегенеративных заболеваний
CR20150078A (es) Análogos de piridazina 1,4-disustituida y métodos para el tratamiento de condiciones relacionadas con la deficiencia de smn
EA201690521A1 (ru) Способ получения замещенных 5-фтор-1h-пиразолопиридинов
EA202190619A1 (ru) Противовирусные соединения
EA201792471A1 (ru) Бигетероарильные соединения и их применения
EA201201030A1 (ru) 5-алкинилпиримидины
EA201391485A1 (ru) Способы и композиции для лечения нейродегенеративных заболеваний
EA201591122A1 (ru) Гетероциклическое соединение
EA201590381A1 (ru) Замещенные пиразолы, используемые в качестве блокаторов кальциевых каналов n-типа
EA201590296A1 (ru) Дейтерированный ибрутиниб
EA201300388A1 (ru) Соединения замещенного бензамида
EA201492023A1 (ru) Регуляторы пути комплемента и их применение
EA201691141A1 (ru) Соединения против ccr6
EA201791802A1 (ru) СШИТЫЕ ДИГИДРО-4H-ПИРАЗОЛО[5,1-c][1,4]ОКСАЗИНИЛОВЫЕ СОЕДИНЕНИЯ И АНАЛОГИ ДЛЯ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЙ ЦНС
EA201891804A1 (ru) Тетрациклиновые соединения
EA201690755A1 (ru) Солевые и кристаллические формы ингибитора plk-4